Management of High-Grade T1 Bladder Cancer

Jeffrey M. Holzbeierlein, MD, Director of the Division of Urologic Oncology at the University of Kansas Hospital and Director of Clinical Research for the Urology Department at KUMC, talks about how to manage high-grade T1 bladder cancer (HGT1BC). He discusses 5-year progression rates of HGT1BC, pathological substratification of the disease, and risk calculators to estimate patient progression. Dr. Holzbeierlein concludes by discussing enhanced cystoscopy, the value of re-resection, and the importance of bacillus Calmette-Guerin (BCG) maintenance in HGT1BC.

Пікірлер: 3

  • @Wunderpus-photogenicus
    @Wunderpus-photogenicus2 жыл бұрын

    Can anyone answer the following question, please? If a patient is diagnosed to be NMIBC (T-is with carcinoma in-situ cancer), and if he decides (or refuses) to not go through the long (very long) invasive treatment (e.g. years of BCG, cystoscopy, TURBT, repeated numerous times), and insists to go directly with radical cystectomy (RC) and urinary diversion (e.g. Ileal conduit) option, is he allowed to do so, and whether Medicare or other private insurance will cover that? In other words, will such a patient be "forced" to go through years of BCG treatment before he can go to the RC and urinary diversion route? Thanks.

  • @mathews9274

    @mathews9274

    2 жыл бұрын

    is radiation preffarable??

  • @mathews9274
    @mathews92742 жыл бұрын

    is radiation prefferable??